M.A. Convery

Medicine · Health Sciences

26h-index2.2kcitations132works4.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Blood Coagulation and Thrombosis Mechanisms(17), Atrial Fibrillation Management and Outcomes(16), Organometallic Complex Synthesis and Catalysis(14), Metal complexes synthesis and properties(11), Lanthanide and Transition Metal Complexes(11)

Publications132 total

Optimization of Potent and Selective Cyclohexyl Acid ERAP1 Inhibitors Using Structure- and Property-Based Drug Design
ACS Medicinal Chemistry Letters·2024· 4 citedOpen Access
Discovery of GSK251: A Highly Potent, Highly Selective, Orally Bioavailable Inhibitor of PI3Kδ with a Novel Binding Mode
Journal of Medicinal Chemistry·2021· 4 citedOpen Access
PI3 kinase delta in complex with N-[2-(2-fluoro-4-{[4-(propan-2-yl)piperazin-1-yl]methyl}phenyl)pyridin-4-yl]-2-methoxy-5-(morpholin-4-yl)pyridine-3-sulfonamide
2021
GSK137, a potent small-molecule BCL6 inhibitor with in vivo activity, suppresses antibody responses in mice
Journal of Biological Chemistry·2021· 22 citedOpen Access
PI3K Delta in complex with methoxymethyloxathiatetraazatetracyclodocosahexaenedione
2020
Design and Development of a Macrocyclic Series Targeting Phosphoinositide 3-Kinase δ
ACS Medicinal Chemistry Letters·2020· 12 citedOpen Access
Correction to Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel
ACS Medicinal Chemistry Letters·2020· 4 citedOpen Access
Optimization of Orally Bioavailable PI3K delta Inhibitors and Identification of Vps34 as a Key Selectivity Target.
Journal of Medicinal Chemistry·2020· 1 cited
Optimization of Orally Bioavailable PI3Kδ Inhibitors and Identification of Vps34 as a Key Selectivity Target
Journal of Medicinal Chemistry·2019· 18 citedOpen Access
PI3K delta in complex with 2methoxyN[2methoxy5(7{[(2R)4(oxetan3 yl)morpholin2yl]methoxy}1,3dihydro2 benzofuran5yl)pyridin3yl]ethane1 sulfonamide
2019
Discovery of Pyrazolocarboxamides as Potent and Selective Receptor Interacting Protein 2 (RIP2) Kinase Inhibitors
ACS Medicinal Chemistry Letters·2019· 26 citedOpen Access
RIP2 kinase catalytic domain complex with (5S,6S,8R)-2-(benzo[d]thiazol-5-yl)-6-hydroxy-4,5,6,7,8,9-hexahydro-5,8-methanopyrazolo[1,5-a][1,3]diazocine-3-carboxamide
2019
RIP2 Kinase Catalytic Domain complex with 5-Amino-1-Phenylpyrazole-4-Carboxamide.
2019
RIP2 Kinase Catalytic Domain complex with 5amino1tertbutyl3(3methoxyphenyl)1H pyrazole4carboxamide.
2019
Correction to Discovery of 3-Oxabicyclo[4.1.0]heptane, a Non-nitrogen Containing Morpholine Isostere, and Its Application in Novel Inhibitors of the PI3K-AKT-mTOR Pathway
Journal of Medicinal Chemistry·2019
CCDC 1864315: Experimental Crystal Structure Determination
The Cambridge Structural Database·2019· 1 citedOpen Access
Discovery of 3-Oxabicyclo[4.1.0]heptane, a Non-nitrogen Containing Morpholine Isostere, and Its Application in Novel Inhibitors of the PI3K-AKT-mTOR Pathway
Journal of Medicinal Chemistry·2019· 24 citedOpen Access
Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[<i>d</i>]thiazol-5-ylamino)-6-(<i>tert</i>-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases
Journal of Medicinal Chemistry·2019· 65 citedOpen Access
PI3K delta in complex with N(2chloro5phenylpyridin3yl)benzenesulfonamide
2018
Discovery of Potent, Efficient, and Selective Inhibitors of Phosphoinositide 3-Kinase δ through a Deconstruction and Regrowth Approach
Journal of Medicinal Chemistry·2018· 12 citedOpen Access
page 1 of 7Next →

Frequent Co-authors

Christine J. Cardin(14), Robert J. Young(11), Chuen Chan(10), Stefan Senger(10), Nigel S. Watson(10), David Brown(9), Gita P. Shah(8), Michael Devereux(8), Cynthia L. Burns-Kurtis(7), Anthony J. Pateman(7), David J. Cardin(7), Matthew Campbell(6), Henry A. Kelly(6), Savvas Kleanthous(6), Angela Patikis(6), John R. Toomey(6), Malachy McCann(6), Bartholomew J. Votta(5), Robert W. Marquis(5), Adam K. Charnley(5)